B
Bull
Bull · 25%MDAI
$2.22
Precio del escenario
$1.570
-0.058 (-3.68%)Al cierre
Loading chart…
- High
- 1.640
- Open
- 1.620
- VWAP
- 1.59
- Vol
- 100.15K
- Mkt Cap
- 31.47M
- Low
- 1.570
- Amount
- 159.57K
- EV/EBITDA, TTM
- -1.37
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
AI analysis of Spectral AI Inc (MDAI)
holdGiven the current price of $1.57 and the forward P/E ratio of 52.36, the stock is not an attractive buy at this moment. While the recent FDA clearance for the DeepView System is a positive catalyst, the RSI at 37.84 indicates that the stock is oversold, suggesting potential for recovery. However, the net income has been negative, with a loss of $4,176,000 in Q2 2026, which poses a significant risk.
Métricas de valoración
The current forward P/E ratio for Spectral AI Inc (MDAI) is 52.36, compared to its 5-year average forward P/E of 4.61.
Alphio AI Price Scenarios for MDAI
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.507-29GlobenewswireSpectral AI to Report Q2 Financial Results on August 11, 2026
5.007-08NewsfilterSpectral AI Appoints New Chief Commercial Officer
- 8.506-25Newsfilter
Spectral AI Wins First Prize at British Burn Association Conference
- 8.506-12Newsfilter
Spectral AI Celebrates Wound Healing Awareness Month with AI Innovations
- 8.506-11Newsfilter
Spectral AI to Showcase DeepView System at British Burn Association Annual Meeting
MDAI FAQ — answered by Alphio AI
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Given the current price of $1.57 and the forward P/E ratio of 52.36, the stock is not an attractive buy at this moment. While the recent FDA clearance for the DeepView System is a positive catalyst, the RSI at 37.84 indicates that the stock is oversold, suggesting potential for recovery. However, the net income has been negative, with a loss of $4,176,000 in Q2 2026, which poses a significant risk.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.